Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1 Neoplasms 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1

Interventions

Dexamethasone 21 Rituximab 13 Paclitaxel 10 Gemcitabine 10 Cisplatin 10 pomalidomide 9 Lenalidomide 9 Carboplatin 8 Bortezomib 8 Cyclophosphamide 7 Drug Therapy 5 Cytarabine 5 selinexor 4 daratumumab 4 carfilzomib 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 ibrutinib 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 galiximab 2 eculizumab 2 durvalumab 2 blinatumomab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡